Ascendis Pharma A/S (Ascendis Pharma A/S) LT-Debt-to-Total-Asset : 0.75 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma A/S LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ascendis Pharma A/S's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.75.

Ascendis Pharma A/S's long-term debt to total assets ratio increased from Dec. 2022 (0.44) to Dec. 2023 (0.75). It may suggest that Ascendis Pharma A/S is progressively becoming more dependent on debt to grow their business.

Ascendis Pharma A/S LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ascendis Pharma A/S's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S LT-Debt-to-Total-Asset Chart

Ascendis Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

0.09

0.44

0.75

Ascendis Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.44	0.50	0.58	0.73	0.75

Ascendis Pharma A/S LT-Debt-to-Total-Asset Calculation

Ascendis Pharma A/S's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	674.88	/	900.313
	=	0.75

Ascendis Pharma A/S's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	674.88	/	900.313
	=	0.75

Ascendis Pharma A/S (NAS:ASND) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ascendis Pharma A/S LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.